# Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19)

> **NCT05087368** · PHASE2 · UNKNOWN · sponsor: **D'Or Institute for Research and Education** · enrollment: 520 (estimated)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca)
- **BIOLOGICAL:** CoronaVac (Sinovac Biotech)
- **BIOLOGICAL:** Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)

## Key facts

- **NCT ID:** NCT05087368
- **Lead sponsor:** D'Or Institute for Research and Education
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-01
- **Primary completion:** 2022-04-01
- **Final completion:** 2022-04-01
- **Target enrollment:** 520 (ESTIMATED)
- **Last updated:** 2021-10-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05087368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05087368, "Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05087368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*